Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1842-1848

  Liu, XueQiao ^a   Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN B1; CYCLIN D3; GLYCOGEN SYNTHASE KINASE 3BETA; MUTANT PROTEIN; OPEN READING FRAME 12 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL POPULATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENETIC TRANSFECTION; HERPES ZOSTER; HUMAN; HUMAN CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

CELL CYCLE; CELL LINE; HERPESVIRUS 3, HUMAN; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 84873052382     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02395-12     Document Type: Article

References (52)

1. Scheid MP, Woodgett JR. 2001. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell Biol. 2:760-768.
2. Engelman JA. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9:550-562.
3. Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345.
4. Datta SR, Dudek H, Tao X, Masters S, Fu HA, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 91:231-241.
5. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21- 35.
6. Laing JM, Smith CC, Aurelian L. 2010. Multi-targeted neuroprotection by the HSV-2 gene ICP10PK includes robust bystander activity through PI3-K/Akt and/or MEK/ERK-dependent neuronal release of vascular endothelial growth factor and fractalkine. J. Neurochem. 112:662- 676.
7. Golembewski EK, Wales SQ, Aurelian L, Yarowsky PJ. 2007. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity. Exp. Neurol. 203:381-393.
8. Smith CC, Kulka M, Wymer JP, Chung TD, Aurelian L. 1992. Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation. J. Gen. Virol. 73:1417-1428.
9. Chen YR, Liu MT, Chang YT, Wu CC, Hu CY, Chen JY. 2008. Epstein-Barr virus latent membrane protein 1 represses DNA repair through the PI3K/Akt/FOXO3a pathway in human epithelial cells. J. Virol. 82:8124-8137.
10. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. 2003. Epstein- Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 278:3694-3704.
11. Portis T, Longnecker R. 2004. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/ Akt pathway. Oncogene 23:8619-8628.
12. Fukuda M, Longnecker R. 2007. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J. Virol. 81:9299-9306.
13. Ehrhardt C, Marjuki H, Wolff T, Nurnberg B, Planz O, Pleschka S, Ludwig S. 2006. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell. Microbiol. 8:1336-1348.
14. Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, Bode JG, Schmolke M, Ludwig S. 2007. Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J. Virol. 81:3058-3067.
15. Saito K, Saito M, Taniura N, Okuwa T, Ohara Y. 2010. Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. Virology 403:173-180.
16. Liu Y, Wang Y, Yamakuchi M, Masuda S, Tokioka T, Yamaoka S, Maruyama I, Kitajima I. 2001. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax. Oncogene 20:2514-2526.
17. Avota E, Avots A, Niewiesk S, Kane LP, Bommhardt U, ter Meulen V, Schneider-Schaulies S. 2001. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat. Med. 7:725-731.
18. Dunn EF, Connor JH. 2011. Dominant inhibition of Akt/protein kinase B signaling by the matrix protein of a negative-strand RNA virus. J. Virol. 85:422- 431.
19. Buchkovich NJ, Yu Y, Zampieri CA, Alwine JC. 2008. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-AktmTOR signalling pathway. Nat. Rev. Microbiol. 6:266-275.
20. Rahaus M, Desloges N, Wolff MH. 2007. Varicella-zoster virus requires a functional PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication. Cell. Signal. 19:312-320.
21. Liu X, Li Q, Dowdell K, Fischer ER, Cohen JI. 2012. Varicella-zoster virus ORF12 protein triggers phosphorylation of ERK1/2 and inhibits apoptosis. J. Virol. 86:3143-3151.
22. Rahaus M, Desloges N, Wolff MH. 2005. ORF61 protein of Varicellazoster virus influences JNK/SAPK and p38/MAPK phosphorylation. J. Med. Virol. 76:424-433.
23. Wagner MJ, Smiley JR. 2011. Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling. J. Virol. 85:2803-2812.
24. Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y. 2007. Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. J. Gen. Virol. 88:13-18.
25. Wei L, Hou L, Zhu S, Wang J, Zhou J, Liu J. 2011. Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85alpha subunit of PI3K. Virology 417:211-220.
26. Werden SJ, Lanchbury J, Shattuck D, Neff C, Dufford M, McFadden G. 2009. The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. J. Virol. 83:12068-12083.
27. Smith CC, Nelson J, Aurelian L, Gober M, Goswami BB. 2000. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J. Virol. 74:10417-10429.
28. Matsuda M, Suizu F, Hirata N, Miyazaki T, Obuse C, Noguchi M. 2010. Characterization of the interaction of influenza virus NS1 with Akt. Biochem. Biophys. Res. Commun. 395:312-317.
29. Khattar E, Mukherji A, Kumar V. 2012. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation. FEBS J. 279:1220-1230.
30. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ, McFadden G. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrinrepeat host range factor. Proc. Natl. Acad. Sci. U. S. A. 103:4640-4645.
31. Wang H, Brown J, Martin M. 2011. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53:130-140.
32. Vanhaesebroeck B, Stephens L, Hawkins P. 2012. PI3K signalling: thepath to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13:195- 203.
33. Leisenfelder SA, Moffat JF. 2006. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin- dependent kinase activity. J. Virol. 80:5577-5587.
34. Rahaus M, Desloges N, Wolff MH. 2004. Replication of varicella-zoster virus is influenced by the levels of JNK/SAPK and p38/MAPK activation. J. Gen. Virol. 85:3529-3540.
35. Rahaus M, Desloges N, Wolff MH. 2006. Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway. J. Gen. Virol. 87:749-758.
36. Gober MD, Laing JM, Thompson SM, Aurelian L. 2006. The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures. Brain Res. 1119:26-39.
37. Li S, Carpenter D, Hsiang C, Wechsler SL, Jones C. 2010. Herpes simplex virus type 1 latency-associated transcript inhibits apoptosis and promotes neurite sprouting in neuroblastoma cells following serum starvation by maintaining protein kinase B (AKT) levels. J. Gen. Virol. 91: 858-866.
38. Chuluunbaatar U, Mohr I. 2011. A herpesvirus kinase that masquerades as Akt: you don't have to look like Akt, to act like it. Cell Cycle 10:2064-2068.
39. Norman KL, Sarnow P. 2010. Herpes simplex virus is Akt-ing in translational control. Genes Dev. 24:2583-2586.
40. Camarena V, Kobayashi M, Kim JY, Roehm P, Perez R, Gardner J, Wilson AC, Mohr I, Chao MV. 2010. Nature and duration of growth factor signaling through receptor tyrosine kinases regulates HSV-1 latency in neurons. Cell Host Microbe 8:320-330.
41. Tiwari V, Shukla D. 2010. Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry. J. Gen. Virol. 91:3002-3009.
42. Davies MA. 2012. The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142-147.
43. Madhunapantula SV, Mosca PJ, Robertson GP. 2011. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol. Ther. 12:1032-1049.
44. Barel M, Balbo M, Le Romancer M, Frade R. 2003. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively. Eur. J. Immunol. 33:2557-2566.
45. Perkins D, Pereira EF, Gober M, Yarowsky PJ, Aurelian L. 2002. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J. Virol. 76:1435-1449.
46. Tseng LC, Chen RH. 2011. Temporal control of nuclear envelope assembly by phosphorylation of lamin B receptor. Mol. Biol. Cell 22:3306-3317.
47. Hobbs WE, 2nd, DeLuca NA. 1999. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J. Virol. 73:8245-8255.
48. Song B, Yeh KC, Liu J, Knipe DM. 2001. Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions. Virology 290:320-328.
49. Orlando JS, Astor TL, Rundle SA, Schaffer PA. 2006. The products of the herpes simplex virus type 1 immediate-early US1/US1.5 genes downregulate levels of S-phase-specific cyclins and facilitate virus replication in S-phase Vero cells. J. Virol. 80:4005-4016.
50. Moffat JF, Greenblatt RJ. 2010. Effects of varicella-zoster virus on cell cycle regulatory pathways. Curr. Top. Microbiol. Immunol. 342:67-77.
51. Rowe J, Greenblatt RJ, Liu D, Moffat JF. 2010. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 86:276-285.
52. Taylor SL, Kinchington PR, Brooks A, Moffat JF. 2004. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 78:2853-2862.